Results 121 to 130 of about 125,339 (239)

A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders

Clinical Pharmacology &Therapeutics, EarlyView.
Parkinsonian disorders, including Parkinson's disease, Lewy body dementia, multiple system atrophy, and progressive supranuclear palsy, are progressive neurodegenerative conditions with no treatment options to slow disease progression. This systematic review provides an overview of evidence of disease‐modifying therapies that have been evaluated in ...
Pepijn P.N.M. Eijsvogel, Lars M.G. Smits, Philip H.C. Kremer, Geert Jan Groeneveld   +3 more
wiley   +1 more source

Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential

Toxicology Reports
Glucagon (GCG) like peptide 1 (GLP-1) has emerged as a powerful player in regulating metabolism and a promising therapeutic target for various chronic diseases.
Tohada M. AL-Noshokaty, Rehab Abdelhamid, Nourhan M. Abdelmaksoud, Aya Khaled, Mariam Hossam, Razan Ahmed, Toka Saber, Shahd Khaled, Shereen Saeid Elshaer, Ahmed I. Abulsoud   +9 more
doaj   +1 more source

State‐Level Politics in Forest Governance: The Role of the Narrative‐Policy Nexus in the Brazilian Amazon

Environmental Policy and Governance, EarlyView.
ABSTRACT Deforestation and its social impacts are an enduring challenge in agrarian frontiers, especially in the tropics. Fueled by global demand for commodities, this process is mediated by ideas, concepts, meanings, and policies that uphold socioenvironmental degradation. A key and understudied—arena in which this mediation occurs is the sub‐national
Gabriela Russo Lopes, Fabio de Castro
wiley   +1 more source

Elevated Postoperative Endogenous GLP-1 Levels Mediate Effects of Roux-en-Y Gastric Bypass on Neural Responsivity to Food Cues. [PDF]

, 2017
OBJECTIVE: It has been suggested that weight reduction and improvements in satiety after Roux-en-Y gastric bypass (RYGB) are partly mediated via postoperative neuroendocrine changes.
Barkhof, F, Deacon, CF, Diamant, M, Drent, ML, Gerdes, VEA, Holst, JJ, IJzerman, RG, Ten Kulve, JS, van Bloemendaal, L, Veltman, DJ   +9 more
core  

GLP-1 RA and dual GIP/GLP-1 RA treatment in MODY: a descriptive case series

BMJ Open Diabetes Research & Care
Introduction Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and dual glucose insulinotropic polypeptide (GIP)/GLP-1 RA are widely prescribed, but their effectiveness in different subtypes of maturity-onset diabetes of the young (MODY) is unknown ...
William H Herman, Elif A Oral, Rochelle N Naylor, Brigid Gregg, Alina Z Mehdi, Lily Deng, Colby L Chase, Maria Cristina Foss-Freitas, Mansa Krishnamurthy, David T Broome   +9 more
doaj   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, Ribeya Awaes‐Mahmood, Justyna Kaczmarek, Daniel Black Boada, Rosa Thuemmler, Sam Philip   +7 more
wiley   +1 more source

Cardioprotective effects of GLP‐1(28‐36a): A degraded metabolite or GLP‐1’s better half?

Journal of Diabetes Investigation, 2020
Yangyang Liu, Sodai Kubota, Katsumi Iizuka, Daisuke Yabe   +3 more
doaj   +1 more source

Connecting the dots: A narrative review of the relationship between heart failure and cognitive impairment

ESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.
Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi, Maria Giulia Bellicini, Marianna Adamo, Andrea Pilotto, Marco Metra, Alessandro Padovani, Riccardo Proietti   +6 more
wiley   +1 more source

Semaglutide normalizes increased cardiomyocyte calcium transients in a rat model of high fat diet‐induced obesity

ESC Heart Failure, Volume 12, Issue 2, Page 1386-1397, April 2025.
Sequeira et al. reveal how the glucagon‐like peptide‐1 receptor agonist (GLP‐1‐RA) semaglutide restores cardiomyocyte function in rats subjected to a high‐fat/high‐fructose diet (HFD). Employing fluorescence‐ and patch‐clamp technology in isolated cardiac myocytes, they demonstrate that semaglutide reverses HFD‐induced activation of L‐type calcium ...
Vasco Sequeira, Julia Theisen, Katharina J. Ermer, Marie Oertel, Anton Xu, David Weissman, Katharina Ecker, Jan Dudek, Martin Fassnacht, Alexander Nickel, Michael Kohlhaas, Christoph Maack, Ulrich Dischinger   +12 more
wiley   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source